Company News

Share this article:

Sen. Chuck Grassley (R-IA) has written to Pfizer requesting details about payments the company made to 149 Harvard Medical School faculty members and doctors. A Pfizer spokesperson told the New York Times that the company “will fully cooperate with Senator Grassley's request for information.”

 

Vertex Pharmaceuticals has acquired Canadian drugmaker ViroChem Pharma for $100 million in cash, and 9.9 million shares of Vertex common stock. The acquisition adds two early-stage hepatitis C drugs to the company's portfolio, VCH-222 and VCH-759.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.